David M. Jennings Net Worth

The estimated Net Worth of David M. Jennings is at least $35.1 Тысяча dollars as of 1 June 2016. David Jennings owns over 957 units of Endologix stock worth over $11,062 and over the last 11 years David sold ELGX stock worth over $24,021.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Jennings ELGX stock SEC Form 4 insiders trading

David has made over 2 trades of the Endologix stock since 2016, according to the Form 4 filled with the SEC. Most recently David sold 957 units of ELGX stock worth $12,010 on 1 June 2016.

The largest trade David's ever made was selling 957 units of Endologix stock on 1 June 2016 worth over $12,010. On average, David trades about 273 units every 0 days since 2013. As of 1 June 2016 David still owns at least 50,281 units of Endologix stock.

You can see the complete history of David Jennings stock trades at the bottom of the page.

What's David Jennings's mailing address?

David's mailing address filed with the SEC is 2, Musick, Irvine Spectrum, Irvine, Orange, California, 92618, United States of America.

Insiders trading at Endologix

Over the last 22 years, insiders at Endologix have traded over $72,068,611 worth of Endologix stock and bought 306,824 units worth $2,023,811 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott и Capital Management Lp Camber. On average, Endologix executives and independent directors trade stock every 27 days with the average trade being worth of $13,088. The most recent stock trade was executed by Dan Lemaitre on 4 September 2020, trading 51,844 units of ELGX stock currently worth $2,592.

What does Endologix do?

Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.

Complete history of David Jennings stock trades at Endologix

Endologix executives and stock owners

Endologix executives and other stock owners filed with the SEC include:

• Dan Lemaitre,
  Director
• Leslie V Norwalk,
  Director
• David M. Jennings,
  VP-Human Resources
• Iii Thomas F Zenty,
  Director
• Gregory D Waller,
  Director
• Michael V. Chobotov,
  Chief Technology Officer
• Amanda L. De Palma,
  VP, Global Marketing
• John D Mc Dermott,
  Chief Executive Officer
• Christopher G. Chavez,
  Director
• James Edward Machek,
  VP-Research & Development
• Shari L O'quinn,
  VP, Clinical & Regulatory
• Thomas Wilder,
  Director
• Guido J Neels,
  Director
• Jose A. Lima,
  VP-Quality
• Joseph A. De John,
  General Manager, Asia & Pac
• Jeremy B. Hayden,
  General Counsel
• Matthew Thompson,
  Chief Medical Officer
• Laura Nagel,
  VP, Quality
• Stefan Schreck,
  Vice President
• Vaseem Mahboob,
  Chief Financial Officer
• Jeffrey F Odonnell,
  Director
• Capital Management Lp Camber,
  
• International, L.P. Elliott,
  10% owner
• Leonard M. Greenstein,
  VP Finance & Corp Controller
• Greef Roderick De,
  Director
• Robert D Mitchell,
  President
• Martin Tyler,
  V.P. Global Marketing
• Franklin D Brown,
  Executive Chairman
• Woodlands Health Ventures F...,
  10% owner
• Paul Mccormick,
  Chief Executive Officer & Pres
• Associates, L.P. Elliott,
  10% owner
• Edward Diethrich,
  Director
• Daniel Hawkins,
  Vice Pres - Global Marketing
• Todd Abraham,
  VP of Operations
• Janet Mary Fauls,
  Vice President RA/QA/QC
• Charles Steele Love,
  VP-Clinical Affairs
• Shelley B Thunen,
  Chief Financial Officer
• Cecile Ferracci,
  General Manager, Europe
• Ronald H Coelyn,
  Director
• John Onopchenko,
  CEO and Director
• Karen Uyesugi,
  Vice President
• Robert John Krist,
  Chief Financial Officer
• Ruth Anne Lyons,
  VP Global Marketing
• Gary I. Sorsher,
  Vice President - Quality
• Joseph A Bishop,
  Vice President Research & Devl
• Jeffrey H Thiel,
  Director
• Maurice Buchbinder,
  Director
• Herbert H Mertens,
  Vice President of Sales/Mktg
• Michael R Henson,
  Director
• David M Richards,
  Chief Financial Officer & Secr
• John Zehren,
  Chief Commercial Officer
• Jeff Fecho,
  Chief Quality Officer
• Jane E Kiernan,
  Director
• Cynthia Buch Pinto,
  Interim CFO
• Timothy Nicholas Brady,
  Controller and Corp Secretary